Country: Ísrael
Tungumál: enska
Heimild: Ministry of Health
MELATONIN
NEURIM PHARMACEUTICALS (1991) LTD, ISRAEL
N05CH01
TABLETS PROLONGED RELEASE
MELATONIN 2 MG
PER OS
Required
NEURIM PHARMACEUTICALS LIMITED
MELATONIN
MELATONIN
Short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
2023-11-30
29.06.2023 _Page 1 of 4 _ Patient Leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986 This medicine is sold only with a doctor’s prescription _ _ Circadin Prolonged-release tablets Composition: Each tablet contains 2 mg melatonin (Melatonin 2mg) Inactive ingredients: See list in section 6 and also in the section "Important information about some of the medicine's ingredients". - Read the leaflet in its entirety before using the medicine . This leaflet contains concise information about the medicine. If you have any further questions, please contact your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if you think that their medical condition is similar to yours. - The medicine is intended for adults over the age of 55. 1. What is the medicine intended for? Melatonin, the active ingredient in Circadin, belongs to a group of natural hormones produced by the body. Circadin is used for a short-term treatment of primary insomnia (sleeplessness, difficulty falling asleep or staying asleep or poor quality of sleep) in patients aged 55 or over. Insomnia is defined as 'primary' when it is not the result of an identified cause, such as a medical, mental or environmental condition. Therapeutic group: A hormone secreted by the body. 2. Before you use the medicine Do not use this medicine if - you are sensitive (allergic) to the active ingredient or to any of the other ingredients of this medicine (a list of the inactive ingredients can be found in section 6). Special warnings regarding the use of this medicine: Before treatment with Circadin , tell your doctor if: - You are pregnant or breastfeeding (see "Pregnancy and breastfeeding" section) . - You are suffering from liver or kidney disorders. Using Circadin is not recommended in these conditions since no studies on Circadin were conducted in people with liver or kidney diseases. - You are suffering from intolerance to certain sugars. - You are suffering from an autoimmune di Lestu allt skjalið
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Circadin 2 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 2 mg melatonin. Excipient with known effect: each prolonged-release tablet contains 80 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. White to off-white, round, biconvex tablets 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Circadin is indicated for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. 4.2 Posology and method of administration Posology The recommended dose is 2 mg once daily, 1-2 hours before bedtime and after food. This dosage may be continued for up to thirteen weeks. _Paediatric population _ The safety and efficacy of Circadin in children aged 0 to 18 years has not yet been established. No data are available. _Renal impairment _ The effect of any stage of renal impairment on melatonin pharmacokinetics has not been studied. Caution should be used when melatonin is administered to such patients. _Hepatic impairment _ There is no experience of the use of Circadin in patients with liver impairment. Published data demonstrates markedly elevated endogenous melatonin levels during daytime hours due to decreased clearance in patients with hepatic impairment. Therefore, Circadin is not recommended for use in patients with hepatic impairment. Method of Administration Page 1 of 9 Page 2 of 9 Oral use. Tablets should be swallowed whole to maintain prolonged release properties. Crushing or chewing should not be used to facilitate swallowing. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 Special warnings and precautions for use Circadin may cause drowsiness. Therefore the product should be used with caution if the effects of drowsiness are likely to be associated with a risk to safety. No clinical data Lestu allt skjalið